Subsidiary of Fuan Pharmaceutical (300194.SZ) plans to invest 428 million yuan in the construction of a green and intelligent high-end production site for raw materials.

Fuan Pharmaceutical (300194.SZ) announced that the company has approved a proposal regarding the investment and construction project of its subsidiary. The company has agreed for its wholly-owned subsidiary, Fuan Pharmaceutical Group Chongqing Bosch Pharmaceutical Co., Ltd. ("Bosch Pharmaceutical"), to invest in the construction project of "raw material pharmaceutical greenization, intelligent high-end production site" in Chongqing's Changshou District Bosch Pharmaceutical Factory area. The project is estimated to have a total investment of 428 million yuan and a construction period of two years. The main purpose of this project is to meet the future development needs of Bosch Pharmaceutical, increase production capacity, and adapt to market demands. With the continuous approval of the company's raw material pharmaceutical products in recent years, the demand for Bosch Pharmaceutical's production capacity has gradually increased. Keeping in mind future development needs, the company plans to construct the aforementioned project. The implementation of this project will increase Bosch Pharmaceutical's production capacity, better adapt to market demands, optimize its product structure, enhance its product and market competitiveness, and promote the long-term development of the company's raw material pharmaceutical business segment.